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Introduction: Transforming growth factor β (TGF-β) is thought to be
a vasoprotective cytokine. Numerous reports confirm its significance in blood
and plaques. There is, however, a lack of information on the molecular
mechanisms involving TGF-β in circulating inflammatory cells in atherogenesis. 
The aim of the study was to assess gene expression of TGF-β and its receptors
in monocytes from patients with acute coronary syndromes (ACS) and the effect
of standard treatment on the studied genes.
Material and methods: The study was carried out in 32 patients with ACS and
15 healthy subjects. Gene expression of TGF-β and receptors TGF-βRI and TGF-βRII
was evaluated on day 1 and 5 in the study group and once in controls. 
The number of mRNA copies isolated from monocytes was assessed by QRT-PCR. 
Results: Monocytes of ACS patients showed slightly elevated transcriptional
activity of TGF-β1 and its receptors RI and RII genes (0.29 ±0.043 vs. 0.08 ±0.020,
p = 0.05; 0.071 ±0.022 vs. 0.036 ±0.023, p < 0.05; 0.134 ±0.020 vs. 0.048 ±0.016,
p < 0.05, respectively). After 5-day standard treatment modest reduction of 
TGF-βRI expression was observed. The studied genes’ expression was unrelated
to ejection fraction, myocardial necrosis markers, GRACE score, time from the
onset of pain to percutaneous coronary intervention and angiographic findings.
Among risk factors family history of CAD was associated with increased 
TGF-βRI expression. Moreover, the presence of 4 or more classic risk factors
correlated with higher TGF-βRI expression.
Conclusions: Monocytes of ACS patients demonstrate overexpression of TGF-β1
and its receptors’ genes. Five-day standard treatment downregulated the TGF-
βRI gene but did not affect TGF-β1 and TGF-βRII.
Key words: monocytes, gene expression, transforming growth factor β, acute
coronary syndromes.
Introduction
Acute coronary syndromes (ACS), including myocardial infarction (MI)
and unstable angina (UA), are among the leading causes of death in
Western societies and have become the major concern of clinical
cardiology. A number of studies over the past two decades have revealed
that ACS is primarily caused by atherosclerotic plaque rupture followed by
intravascular thrombosis resulting in total or partial coronary artery
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occlusion. Many factors responsible for the plaque
vulnerability, including inflammatory factors,
coagulation disturbances and endothelial
dysfunction, have been described [1]. Recent
molecular studies have revealed altered trans  -
criptional activity of many pro- and anti-inflam  -
matory genes involved in plaque formation and
rupture, both in atherosclerotic plaque itself and in
circulating inflammatory cells in patients with ACS.
Transforming growth factor β (TGF-β) is a cyto  kine
engaged in a wide range of physiological and
pathological processes [2]. Apart from embryonic
development and cell growth control, it participates
in wound formation, carcinogenesis, inflammation,
and fibrosis. Transforming growth factor β signalling
is mediated by two major receptors: RI and RII –
serine/threonine kinase type proteins, which
eventually activate TGF-β dependent transcription
factors [3]. 
In the pathophysiology of the cardiovascular
system TGF-β seems to act mostly protectively due
to its anti-inflammatory and anti-atherogenic action
[4]. It inhibits activation of macrophages and 
T-lymphocytes, and reduces vascular smooth muscle
cell proliferation [5, 6]. In experimental models TGF-β
inhibits inflammatory cell migration into the
subintimal space and stimulates extracellular matrix
formation [7, 8]. Although there are some data on
the action of TGF-β at the protein level, not much
is known about the molecular disturbances of 
TGF-β gene transcription in cardiovascular diseases. 
Monocytes are one of two major populations of
blood derived immune cells and are involved in
atherosclerotic plaque formation, growth and
rupture by producing numerous inflammation
modulating factors. While it is difficult to obtain the
plaque infiltrating immune cells, circulating blood
cells are a good source of information on the
molecular mechanism of the inflammatory reaction
in atherosclerosis. Often used for these purposes,
peripheral blood mononuclear cells (PBMC), despite
some advantages, are a heterogeneous population. 
Therefore, the aim of the study was to assess:
(1) gene expression of TGF-β and its receptors 
in monocytes from patients with ACS, (2) the
correlation between expression of the studied
genes and classical risk factors of CAD, and (3) the




The study was carried out on:
•  32 patients with ACS [aged 56.3 ±8.2 years 
(mean ± SD)] including 14 patients with ST
elevation myocardial infarction (STEMI), 9 patients
with non-ST elevation myocardial infarction
(NSTEMI) and 9 patients with unstable angina,
with no history of CAD, and
•  15 sex- and age-matched healthy subjects 
(C = control group).
In each patient the full blood cell count,
leukocyte differentiation, creatine kinase (CK), 
CK MB, troponin I, hsCRP, creatinine, glycaemia and
lipid parameters were measured. Patients with
previously diagnosed CAD, including those with
a history of MI and coronary revascularization, were
excluded. Also, chronic inflammatory diseases,
chronic heart failure, chronic kidney disease (eGFR
Monocyte TGF-β in ACS patients
Number of patients treated [%] Average dose/day [mg] 
STEMI NSTEMI UA STEMI NSTEMI UA
ASA  14 (100%) 9 (100%) 9 (100%) 128  108  116 
Clopidogrel 14 (100%) 9 (100%) 9 (100%) 75 75 75
Statins: 14 (100%) 9 (100%) 9 (100%) – – –
• Simvastatin 3 1 3 26 20 20
• Atorvastatin 11 8 6 38 37.5 33
β-Blockers:  13 (93%) 8 (89%) 7 (78%) – – –
• Metoprolol 10 5 6 57 45 46
• Bisoprolol 3 3 1 4.6 2.9 2.5
ACE inhibitors:  11 (79%) 8 (89%) 9 (100%) – – –
• Ramipril 8 8 8 3.75 4.1 3.4
• Quinapril 3 0 1 15.8 – 5
Other:
• Spironolactone 7 (50%) 2 (22%) 0 32 37.5 –
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< 90 ml/min/1.73 m2 calculated with MDRD), as well
as diabetes mellitus, were exclusion criteria. All ACS
patients underwent primary coronary intervention
and were treated according to European Society of
Cardiology Guidelines for management in ACS. All
subjects received ASA, clopidogrel and statin.
Angiotensin convertase enzyme inhibitors (82%)
and β-blockers (82%) were administered unless
contraindicated (Table I). Control subjects had
a standard exercise treadmill test performed (Bruce
protocol). Detailed characteristics of studied groups
including ACS risk profile are shown in Table II.
Written informed consent was obtained from each
participant of the study. 
Blood samples were collected from the basilic
vein into tubes containing EDTA. The samples were
obtained from patients within 12 h after the onset
of chest pain and again after 5 days of standard
treatment, including percutaneous coronary
intervention (PCI). Time from the onset of chest
pain to first blood sampling is indicated in Table III.
In all cases the blood (day 1 sample) was drawn
before PCI and before introducing full pharma  -
cological treatment. Before the collection patients
could only receive emergency ACS treatment e.g.
ASA, heparin, nitrates and clopidogrel. In the control
group blood was taken once. Upon blood sampling,
the monocytes were immediately isolated using
RosetteSep (StemCell Technologies, USA) monocyte
separation kits. The procedure was performed
according to the producer’s manual. Purity of
isolated monocytes was > 96%. After isolation
monocytes were stored at –70°C in RNAlater
(Qiagen, USA) stabilization reagent until RNA
extraction.
RNA extraction
Total RNA was extracted from monocytes using
a modified Chomczynski and Sacchi method. All
Study group
ACS (all) (n = 32) STEMI (n = 14) NSTEMI (n = 9) UA (n = 9)
Time from the onset of chest pain [h] 7.2 [1-24] 4.2 [1-10] 8.9 [2-24] 10.1 [2-24]
One-vessel/multivessel disease [n/n] 21/11 10/4 6/3 5/4
PCI Target vessel [LAD/LCX/RCA] 14/7/11 6/2/6 5/4/0 3/1/5
Ejection fraction [%] 53 ±1.4 50 ±2.0 55 ±2.0 56 ±3.0
Myocardial necrosis markers:
• CK [UI/l] 1471 ±365.6 27834 ±674.8 773 ±233.5 124 ±8.8
• CK-MB [UI/l] 149 ±31.4 256 ±55.8 111 ±32.4 19.3 ±1.33
• Troponin I [ng/ml] 10.5 ±2.18 19.6 ±3.17 7.9 ±3.19 < 0.01
GRACE: In hospital death [% range] – 16-25 12-18 6-12
GRACE: 6-month death or MI [% range] – 2-6 1-4 1-4
eGFR (MDRD) 101.5 ±13.4 103.9 ±15.4 98.7 ±10.4 100.0 ±13.0
Table III. Clinical characteristics of ACS
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Parameter Study group Control group
ACS (all)S ubgroups
(n = 15)
(n = 32) STEMI (n = 14) NSTEMI (n = 9) UA (n = 9)
Age [years ± SD] 56.3 ±8.2 56.6 ±10.2 56.6 ±4.4 55.3 ±8.6 51 ±8.6
Sex (M/F) 26/6 12/2 7/2 7/2 9/6
Family history, n (%) 10 (31) 3 (21) 3 (33) 4 (44) 5 (33)
Smoking, n (%) 24 (75) 8 (57) 7 (77) 7 (77) 2 (13)
Hypertension, n (%) 21 (66) 10 (71) 5 (55) 6 (66) 0
Overweight, n (%) 20 (63) 7 (50) 6 (66) 7 (77) 5 (33)
BMI [kg/m2] 26.6 ±0.56 26.2 ±1.05 26.6 ±1.0 27.3 ±0.8 24.5 ±0.55
Hypercholesterolaemia, n (%) 17 (53) 8 (57) 4 (44) 5 (55) 3 (20)
Hypertriglyceridaemia, n (%) 5 (16) 1 (7) 1 (11) 3 (33) 1 (7)
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extracts were treated with DNase I to avoid
contamination by genomic DNA. The RNA extracts
were qualitatively evaluated by electrophoresis
(sample electrophoresis shown in Figure 1) in 1%
agarose gel stained with ethidium bromide, and
quantified spectrophotometrically (Gene Quant II
by Pharmacia).
Primers 
Primers and probes for amplification of TGF-β1
and its type I (ALK5), and II receptors were
determined using the Primer Express Version 1.0
computer program (PE Applied Biosystems, USA),
and their sequence homologies were checked using
the GenBank database (http://www.ncbi.nlm.nih.
gov/irx/genbank).
Primer sequences were (f – forward; r – reverse):
TGF-β (f) 5’ TGGAACCGGCCTTTCCTGCTTCTCATG 3’,
(r) 5’ GCGGAAGTCAATGTACAGCTGCCGC 3’;
TGF-β receptors;
TGF-β RI   
(f) 5’ ACTGGCAGCTGTCATTGCTGGACCAG 3’,
(r) 5’ CCTGAGCCAGAACCTGACGTTGTCATATCA 3’;
TGF-β RII  (f) 5’ GGCTCAACCACCAGGGCATCCAGAT 3’,
(r) 5’ CTCCCCGAGAGCCTGTCCAGATGCT 3’.
The β-actin gene was used as the endogenous
control and was amplified simultaneously with
assessed genes. Primer sequences used for β-actin
amplification were: 
(f) 5’ TCACCCACATGTGCCCATCTACGA 3’,
(r) 5’ CAGCGGAACCGCTCATTGCCAATGG 3’.
Real-time PCR (QRT-PCR)
In order to determine the number of mRNA
copies for TGF-β and its type I and II receptors,
quantitative reverse transcriptase polymerase chain
reaction (QRT-PCR) was performed using QuantiTect
SYBR Green RT-PCR. Cycling conditions were as
follows: RT – 60°C for 30 min; polymerase activation
– 94°C for 15 min; PCR – 94°C for 15 s and 53-68°C
for 30 s, 40 cycles; final elongation – 72°C for 10 min.
QRT-PCR specificity was confirmed experimentally
by PAA electrophoresis, amplimers’ melting
temperature measurement using ABI PRISM7000
(SYBR Green RT-PCR Kit), and sequence analysis
using ABI PRISM 377 DNA Sequencer (PE Applied
Biosystems). The results are shown as studied gene
to β-actin mRNA level ratio. 
Statistical analysis
All values were expressed as means ± standard
error (AVG ± SEM). Differences were considered to
be significant at p < 0.05. In order to check the
normality of the distribution, the Shapiro-Wilk test
was performed. In case of a normal distribution
Student’s t-test was performed; otherwise the
Mann-Whitney U test was used. To compare two
related variables the Wilcoxon test was used.
Analysis of correlation was performed using the
Spearman test.
The study was accepted by the Ethics Committee
of the Medical University of Silesia. 
The investigation conforms to the principles
outlined in the Declaration of Helsinki.
Results
Basic clinical parameters of ACS patients are
shown in Table II. The results of gene expression
are shown as studied gene to β-actin mRNA level
ratio. 
Compared to healthy subjects, ACS patients
showed slightly elevated transcriptional activity of
genes encoding TGF-β1 (0.29 ±0.043 vs. 0.08 ±0.020,
p < 0.05) and its receptors RI and RII (0.071 ±0.022 vs.
0.036 ±0.023, p < 0.05; 0.134 ±0.020 vs. 0.048 ±0.016,
p < 0.05, respectively). After 5 days of standard
treatment a statistically significant decrease in 
TGF-βRI gene expression was observed (0.071
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Figure 2. Gene expression of TGF-β1 and its receptors
RI i RII in peripheral blood monocytes
Figure 1. Sample RNA electrophoresis in 1% agarose
gel stained with ethidium bromide; each sample
underwent qualitative assessment, then RNA
extracts were quantified spectrophotometrically
ACS (day 1)           ACS (day 5)            Control group
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studied genes’ mRNA level remained similar during
the observation period (Figure 2). Analysis of ACS
subgroups revealed that there are no significant
differences in expression of studied genes at day 1
(although UA tended to have higher TGF-βRI
expression). After 5 days a statistically significant
decrease was observed only for the TGF-βRI gene
in the UA group (Table IV).
Additionally, the RI/RII gene expression ratio was
evaluated. On the day of ACS, the RI/RII ratio was
higher in the study group than in controls (0.75
±0.218 vs. 0.42 ±0.202, p < 0.05), but after 5-day
therapy it decreased significantly (0.75 ±0.218 vs.
0.29 ±0.065, p < 0.05) and was lower than in
controls (0.29 ±0.065 vs. 0.42 ±0.202, p < 0.05).
Again, the decrease was more pronounced in UA
than in MI subgroups (Table IV).
mRNA level of TGF-β1 did not correlate with
either of the receptors. The expression of genes
encoding receptors were not correlated either.
Studied gene expression did not differ among ACS
subgroups.
No major atherosclerosis risk factors (obesity,
smoking, dyslipidaemia, hypertension, age/sex)
affected expression of the studied genes. The
exception was the TGF-βRI gene, whose expression
was higher in ACS patients with family history of
CAD (0.34 ±0.159 vs. 0.11 ±0.04, p < 0.05). Moreover,
the presence of 4 or more classical risk factors
correlated with higher level of TGF-βRI expression
(0.098 ±0.035 vs. 0.028 ±0.008, p < 0.05). hsCRP did
not correlate significantly either with TGF-β
(r = 0.4, p = NS) or with RI and RII receptors 
(r = 0.2, p = NS and r = –0.1, p = NS respectively).
The analysis of the association between studied
gene expression and such clinical variables as
ejection fraction, myocardial necrosis markers (CK,
CKMB, TnI), time to PCI and early risk score
assessed by the GRACE model and GFR did not
reveal any statistically significant relations.
Angiographic findings (e.g. number of affected
vessels and ACS-related artery) were not related to
studied genes’ mRNA levels either. 
Discussion
The effect of TGF-β on the vascular system has
been proven to be protective. According to
Grainger’s hypothesis, lack of TGF-β activity leads
to a two-step process: if the activity is transiently
diminished, an atherosclerotic lesion is formed, but
since TGF-β still stimulates ECM production, and it
results in a stable plaque phenotype, and if TGF-β
activity is chronically reduced, inflammatory
processes may lead to the plaque being converted
to an unstable phenotype. The data come mostly
from animal models of atherosclerosis. The
observations in humans, however, particularly those
assessing plasma levels of TGF-β and their
correlation with clinical manifestation of
atherosclerosis, remain confusing.  
Although Grainger et al. in 1995 published their
data proving that patients with atherosclerosis had
severely depressed circulating levels of TGF-β [9],
some later reports agreed with the findings [10],
while some others did not find any correlation of
TGF-β and atherosclerosis [11] or even suggested
that atherosclerotic patients have increased TGF-β
levels [12, 13]. The discrepancies are mostly due to
methodology: some investigators assessed total
cytokine, while some others assessed active
cytokine. It is noteworthy that investigators who
observed low levels of active TGF-β also noted
similar or even elevated concentrations of total 
TGF-β in the atherosclerotic population compared
to healthy controls. The reason for low levels of
active cytokine in CAD subjects might be that in
this group of patients high levels of TGF-β inhibitors
(e.g. lipoprotein (a), plasminogen activator inhibitor
type 1) are observed [14, 15]. 
Recently the emphasis has been on leukocytes
as a potential source of TGF-β. It is not clear,
however, which population is the main source. In
this study we have observed elevated
transcriptional activity of genes encoding TGF-β1
and its two receptors in circulating monocytes of
ACS patients. If blood monocytes are to be
considered an important source of circulating
cytokines, our finding would confirm the data that
in atherosclerosis TGF-β production is not
diminished or can even be increased. On the other
hand, recent findings of Kempf et al. [16] as well as
our previous report [17] show that TGF-β mRNA
expression in PBMC is lower in CAD subjects. The
reason might be that PBMC are a heterogeneous
group of cells (e.g. a high proportion of
lymphocytes) and our new data seem to provide
more detailed information. Our study showed
increased gene expression of TGF-β in all clinical
Gene ACS subgroups
expression STEMI  NSTEMI UA
(n = 14) (n = 9) (n = 9)
TGFβ-1 (day 1) 0.29 ±0.05 0.23 ±0.05  0.34 ±0.12 
TGFβ-1 (day 5) 0.33 ±0.06 0.26 ±0.05  0.26 ±0.04 
TGFβRI (day 1) 0.04 ±0.01  0.03 ±0.01  0.15 ±0.07 
TGFβRI (day 5) 0.07 ±0.05  0.03 ±0.004 0.02 ±0.004*
TGFβRII (day 1) 0.18 ±0.04  0.10 ±0.02   0.10 ±0.02 
TGFβRII (day 5) 0.11 ±0.04  0.24 ±0.10  0.10 ±0.02 
TGFβRI/RII (day 1) 0.35 ±0.07 0.56 ±0.30 1.47 ±0.61 
TGFβRI/RII (day 5) 0.40 ±0.16 0.22 ±0.06 0.24 ±0.05*
Table IV. Gene expression of TGF-β and its receptors
in ACS subgroups
*p < 0.05 statistically significant difference vs. day 1 values
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forms of ACS with no differences among ACS
subgroups.
Besides TGF-β itself, changes in TGF-β receptor
signalling play an important role in the evolution of
atherosclerotic lesions. In the normal vessel wall,
expression of TGF-β type II receptor predominates,
while in the pathological condition TGF-βRI
signalling increases. In the present study
transcriptional activity of TGF-β receptor genes was
elevated along with the cytokine gene. The RI/RII
expression ratio was the highest on the first day of
ACS, which means that the balance was more
toward the “pathological” RI receptor. Five-day
therapy did not affect either TGF-β1 gene expression
or RII expression, but reduced RI, thus restoring the
balance between “pathological” and “physiological”
receptor. This finding is important considering that
receptor disturbances in TGF-β signalling may have
a profound effect on atherosclerosis progression
[18]. It is noteworthy, however, that the decrease in
TGF-βRI expression and RI/RII ratio was significantly
pronounced only in the UA group. It is possible that
the overlap of necrosis-related inflammatory
reaction in STEMI and NSTEMI subgroups had some
effect on TGF-βR expression on day 5, but the
design of the study does not allow us to address
this issue.
The day 1 sample is considered in the study as
prior to treatment status. As mentioned, before the
collection patients could only receive emergency
ACS treatment, so the treatment given prior to
sampling is unlikely to have had any effect on gene
expression. Five days of treatment did not affect
the monocyte expression of the TGF-β and RII gene.
Although there are a number of articles reporting
the effect of statins, ACE inhibitors and aspirin on
TGF-β [19, 20], multi-drug therapy varying from
patient to patient and the short observation time
did not allow us to observe any major effect on the
studied genes.
Transforming growth factor β seems to be an
independent mechanism in atherogenesis and it is
not surprising that in the study we have not
observed any linkage between gene expression of
TGF-β or its receptors and classical CAD risk factors,
such as hsCRP level, smoking, dyslipidaemia,
hypertension and obesity. There are some reports,
however, to confirm the mechanistic link between
cigarette smoking or dyslipidaemia and TGF-β [21,
22]. Although no correlation was found between
studied genes and particular risk factors, patients
with a higher total risk score (e.g. more than 3 risk
factors) presented with elevated level of TGF-βRI
gene expression, which is further proof that the
balance in the receptors is important in maintaining
proper TGF-β signalling and its protective action. In
the subsequent analysis patients with a family
history of CAD had a higher gene expression of
“pathological” TGF-βRI receptor and, consequently,
increased RI/RII ratio. The gene of TGF-β itself did
not differentiate the groups. There are no data in
the literature to prove that molecular disturbances
in TGF-β signalling might be one of the genetic
backgrounds of atherosclerosis, and this is a novel
finding in this study. A few polymorphisms have
been identified to link genetic background and ACS,
but they all referred to the TGF-β gene, not its
receptors [23].  
Lack of a correlation between studied gene
expression and clinical parameters of ACS (including
EF, time of chest pain before PCI, necrosis markers)
is not surprising given the fact that monocyte gene
expression is more likely to reflect a chronic
inflammatory process and monocyte activation
leading to ACS than the clinical state at the time of
the event. Also renal function (eGFR), which is
strongly associated with cardiovascular risk [24],
due to exclusion criteria was homogeneous in the
studied group and did not correlate with monocyte
gene expression.
One limitation of the study is the number of
patients recruited. An increased number would
possibly reveal some relationships that did not meet
statistical significance here. The exclusion criteria,
however, were set to keep study subgroups
relatively homogeneous. Another issue is that the
study protocol does not allow us to distinguish
whether studied gene expression changes were due
to the chronic atherosclerotic process or acute
plaque rupture. Although a stable CAD group would
provide some more information on this matter, it
is difficult to obtain a relatively homogeneous stable
angina group with similar treatment, which,
presumably, is an important factor affecting gene
expression. 
The altered gene expression observed here in
monocytes of ACS patients reflects a systemic
reaction to atherosclerosis, and the part TGF-β takes
in it. It would be of interest to evaluate it in
lymphocytes as well, and to correlate these findings
with circulating levels of TGF-β. 
In conclusion, monocytes of ACS patients
demonstrate overexpression of TGF-β1 and its
receptors’ genes, which suggests activation of
protective mechanisms in ACS. Increased TGF-βRI
expression in high risk patients may reflect the
significance of this receptor in pathology of
atherosclerosis. Five-day standard treatment
downregulated the TGF-βRI gene but did not affect
TGF-β1 and TGF-βRII.
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